

Investor Newsletter

Issue **03** 2016

 **MicroPort**

CIT 2016

China Interventional Therapeutics in Partnership with TCT

MicroPort® Attends CIT 2016

Shanghai MicroPort Medical (Group) Co ("MicroPort®") recently attended the 14th China Interventional Therapeutics ("CIT 2016") in China National Convention Center in Beijing.

During the opening ceremony of CIT 2016 hosted by Professor Runlin Gao of Fuwai Hospital of Chinese Academy of Medical Sciences and Dr. Martin B. Leon of Columbia University in the City of New York, MicroPort®'s second generation of bioresorbable stent Firesorb™ Bioresorbable Rapamycin Target Eluting Coronary Scaffold System ("Firesorb™") was presented in the live case of the plenary session. The operation was successfully conducted by Professor Shubin Qiao of Fuwai Hospital. CRF Chief Medical Officer Gary Mints made a clear narration of the operation and interacted with the audience. Dr. Martin B. Leon pointed out that Firesorb™ is the thinnest bioresorbable stent and is as effective as most mainstream drug-eluting stents ("DES"). Later, in the forum themed Innovation in Intervention, MicroPort® Chief Technology Officer Dr. Qiyi Luo made a speech of From Firehawk® to Firesorb™: The MicroPort® Innovation, to present the development of MicroPort® DES products to the people in attendance. ▶

On March 18, MicroPort® hosted the Luncheon Satellite Symposium: Evolution of MicroPort® DES Product, co-chaired by Professor Weifeng Shen of Shanghai Ruijin Hospital, Professor Shubin Qiao of Fuwai Hospital, Professor Jianfang Luo of Guangdong General Hospital, Professor Costantino R. Costantini from Brazil and Professor Wasan Udayachalem from Thailand. Professor Kefei Dou of Fuwai Hospital delivered a speech on Development History of MicroPort® Coronary Products, to introduce the performance of MicroPort® coronary devices in the treatment of complex coronary artery diseases. Professor Alfredo E. Rodriguez of Otamendi Hospital released a report on Modifying SYNTAX Score and Improving Outcome after PCI: Insights From 2-Year Follow-up of ERACI IV Study. Pengcheng He with Guangdong General Hospital made a speech on PCI for STEMI Complicated with Pulmonary Edema: Case Report and Individual Experience. Professor Anuruck Jeamanukoolkit of Vejthani Hospital issued Firebird2® Complex Case Report, to demonstrate Firebird2®'s safety and efficacy in treating complex cardiovascular diseases. Their speeches were warmly received and triggered hot discussions.

On March 19, MicroPort® hosted the Twilight Satellite Symposium: Update on Firehawk® Preclinical and Clinical Program. Professor Yuejin Yang of Fuwai Hospital, Professor Yaling Han of the General Hospital of Shenyang Military, Dr. William Wijns of the Cardiovascular Center in Aalst of Belgium, Professor Shaoliang Chen of Nanjing First Hospital, Professor Bo Xu of Fuwai Hospital and Dr. Andreas Baumbach of Bristol Heart Institute were invited to deliver speeches. For instance, Professor Bo Xu and Professor Shaoliang Chen gave lectures on Update of the Firehawk® Target Eluting Stent Clinical Program and Firehawk® Complex Case Reviews respectively. Dr. William Wijns issued a report on Progress of TARGET All Comer Randomized Trial in Europe. Dr. Andreas Baumbach gave a speech on Complex Case Reviews from TARGET All Comer Trial. Firehawk® TARGET All Comer Randomized Trial in Europe is a prospective, multi-center, randomized clinical trial which aims to evaluate Firehawk®'s safety and effect in the clinical application. In the support of a large number of clinical data, Firehawk® is expected to benefit more patients in the Europe as well as the whole world.

MicroPort® Signs Cooperation Agreement with Beijing Weimai Medical Device

MicroPort® and Beijing Weimai Medical Device Co, an interventional equipment developer and producer owned by TCL Healthcare, recently held the signing ceremony of strategic cooperation agreement in MicroPort® headquarters. TCL Healthcare Board Director and Chief Scientist Hongguang Cao, General Manager of Beijing Weimai Medical Device Co He Yang, and MicroPort® Chief Marketing Officer ("CMO") Bo Peng attended the ceremony.

MicroPort®'s cooperation with Beijing Weimai Medical Device Co comes in response to the Guideline of State Council on Promoting Hierarchical Medical System that aims to improve services at county- and township-level health centers, especially in less-developed areas. Under the agreement, the two companies will collaborate through leveraging complementary strengths to penetrate target markets.

MicroPort® CMO Bo Peng said, this agreement brings together the two parties' complementary advantages in product portfolio and distribution network, and is expected to enable the two companies to share procurement opportunities so as to benefit more primary healthcare institutions and patients.

The **13th** International Dead Sea Symposium (IDSS)
on Innovations in Cardiac Arrhythmias and Device Therapy
March 6-9, 2016 | David InterContinental Convention Center, TEL-AVIV



MicroPort® EP Attends 13th IDSS

Shanghai MicroPort EP MedTech Co ("MicroPort® EP"), the wholly owned subsidiary of MicroPort®, attended the 13th International Dead Sea Symposium ("IDSS") on Innovations in Cardiac Arrhythmias and Device Therapy from March 6 to March 9, which is expected to lay a great foundation for introducing MicroPort® electrophysiological products to the Middle East market as well as other markets.

As the first and only Chinese enterprise that participated in IDSS, an annual conference mainly focused on extensively rising technology and innovations of new therapies, MicroPort® EP displayed several electrophysiological devices in its booth, which attracted wild attention from experts in attendance. Many professionals and regional distributors came to inquire about our star product Columbus® 3D EP Navigation System ("Columbus™") and try our FireMagic® Cool 3D Irrigated Ablation Catheter and other products in vitro, and spoke highly of their design concept and main features.



Professor Gan-Xin Yan of Thomas Jefferson University (Philadelphia) and Lankenau Institute for Medical Research visited MicroPort® EP booth, and said he was pleased to see "innovated-in-China" products in the global academic conference, and expected more MicroPort® EP devices coming to international attention. Professor Yunlong Xia with the First Affiliated Hospital of Dalian Medical University and Professor Jiangang Zou with the First Affiliated Hospital of Nanjing University also showed their full affirmation in MicroPort® EP's international appearance. Besides, Israeli Professor Ron Sela and other professionals from North America, Europe and Middle East expressed their interest in MicroPort® EP's products and gained in-depth knowledge about their technical features.

Columbus[®] Granted CFDA Registration Certificate

MicroPort[®] EP recently received the registration certificate of China Food and Drug Administration ("CFDA") for its in-house developed Columbus[®].

Columbus[®], which provides information about the electrical activity of the heart and catheter location in real time, is designed for the diagnosis of arrhythmias and acts as guidance for catheter ablation.

Columbus[®] is the first domestically developed 3D EP navigation system that features real time electromagnetic device tracking with cardiac motion compensation. It offers vivid 3D simulation of the catheter deflectable segment and accurate geometric reconstruction of intra cardiac chambers. With the help of MicroPort[®] EP's FireMagic[®] Cool 3D Irrigated Ablation Catheter that shows precise location of the catheter curve in the body, Columbus[®] provides physicians with a comprehensive solution for the radiofrequency ablation treatment of complex arrhythmias. It also features powerful workstation with integrated ECG recording module, automatic 3D image segmentation of cardiac chambers with one mouse click, and accurate preoperative CT image registration and integration. Meanwhile, the system is all Chinese interface and easy to operate.

Columbus[®] was granted CE approval in 2013 and is the only domestically made 3D EP navigation system with the CE certificate. So far it has been exported to Spain, Turkey and Greece and has gained high market recognition. With its launch in the China market, MicroPort[®] EP will offer more solutions for patients with cardiac arrhythmias in the country.



MicroPort® Angiography Guidewire Obtains CFDA Registration Certificate

MicroPort® gained a CFDA registration certificate for its in-house developed Angiography Guidewire.

The Angiography Guidewire is a sterile disposable surgical accessory. In Seldinger Technique, the Angiography Guidewire is inserted into the vessel through a sheath and then the catheter is threaded over the guidewire to perform angiography examination in a PCI operation. In the process of introducing the catheter, the soft tip of the Angiography Guidewire is always in front of the catheter, so with X-ray observation the surgeon can confirm the position of the catheter and to manoeuvre it to the desired location.

The Angiography Guidewire is an updated version of MicroPort®'s guidewire for Disposable Endovascular Catheter. Compared to the previous guidewire, this Angiography Guidewire has a tip of adjustable diameter, which largely enhances the product's crossability. The structure of guidewire tip with adjustable diameter has obtained national patent.





AAOS Annual Meeting

Several MicroPort employees and sales representatives of MicroPort® Orthopedics attended the world-renowned AAOS 2016 Annual Meeting, which was held from March 1 to March 5 in Orlando Florida. This year's presidential guest speaker was former Heisman Trophy winner and NFL MVP, Roger Staubach. AAOS was founded in 1933 and is the preeminent provider of musculoskeletal education to orthopedic surgeons and others throughout the world.

MicroPort® Orthopedics Attends Annual Meeting of the Japanese Society for Replacement Arthroplasty

MicroPort® Orthopedics recently participated in the 46th Annual Meeting of the Japanese Society for Replacement Arthroplasty as an exhibitor. Around 2,500 surgeons participated in this meeting and lively discussions were carried out.

In this year's annual meeting, there was a session regarding Medial Pivot Knee Design. Meanwhile, MicroPort® Orthopedics sponsored the afternoon seminar mainly focused on EVOLUTION™ Medial-Pivot Knee System design rational. In the seminar that attracted over 130 surgeons, Yukihide MINODA from Department of Orthopedics Surgery of Osaka City University Graduate School of Medicine, was invited to delivered a speech on the present status and prospective of medial pivot total knee arthroplasty.





BASK Meeting in United Kingdom

The British Association for surgery of the Knee (“BASK”) celebrated their annual conference on the banks of the River Mersey in the city of Liverpool. Running from March 30 to March 31, 440 registered delegates shared clinical outcomes, papers and experiences. Key speakers discussed different perspectives of the UK’s soft tissue and arthroplasty practices.

The overseas guest speaker Dr. Barrack delivered the “Lorden Trickey Lecture” on “Total Knee Replacement - the patient's perspective,” concluding that patient satisfaction with their TKR and best possible full functional outcome is the new goal.

Our MicroPort® Orthopedics stand offered visitors the opportunity to see a demo/walk through of the EVOLUTION™ Medial-Pivot Knee System instrument platform. This was well received by those who visited us.

Investor Newsletter

Issue **03** 2016



For more information, please contact:

Hongbin Sun

Chief Financial Officer

Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)

Tel: (86)(21) 38954600

Email: ir@microport.com